HarmoniaMentis

Discover ONTOZRY^®▼ (cenobamate)
- Introducing ONTOZRY^®▼(cenobamate)
- Which patients could benefit from ONTOZRY^®▼ (cenobamate)?
Clinical Practicalities
Efficacy
Safety and tolerability
Contact Us

Omnichannel Campaign 2024

Home
UK HCP
You are here: Omnichannel Campaign 2024

Duration

All
3 - 5 minutes
5+ minutes
10+ minutes

12/12/2024
Article

5 minutes

THINK … EFFICACY, TOLERABILITY & LONG TERM

Show more

Cookie Policy
Terms and conditions of use
Privacy notice
Contact Us

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard for the UK or www.hpra.ie for Ireland. Adverse events and product complaints should also be reported to Angelini Pharma on (UK) +44 2034889643, (ROI) +353 1 584 4671 or UKIReporting@angelinipharma.com

MAT-UKI-0092-P | January 2025

Napier House, 24 High Holborn, WC1V 6AZ, London, United Kingdom

Back to top

;